TY - JOUR
T1 - African green monkeys provide a useful nonhuman primate model for the study of human parainfluenza virus types-1, -2, and -3 infection
AU - Durbin, Anna P.
AU - Elkins, William R.
AU - Murphy, Brian R.
N1 - Funding Information:
We would like to thank Marisa St Claire and Jim Edwards for their care and handling of all the animals used in this study. This work is part of a continuing program of research and development with Wyeth-Lederle Vaccines and Pediatrics through CRADA contract AI-000087.
PY - 2000/5
Y1 - 2000/5
N2 - Human parainfluenza virus (HPIV) types-1, -2, and -3 are significant causes of both upper and lower respiratory tract disease in infants and children. Although there are two live attenuated vaccines for the prevention of HPIV-3 disease in phase 1 clinical trials, vaccines are not currently available for prevention of HPIV-1 or -2 disease. Our laboratory is developing candidate vaccines for the prevention of HPIV-1, -2, and -3 disease, and a suitable nonhuman primate model is needed for evaluation of these vaccine candidates prior to administration to humans. We evaluated the replication of HPIV-1 and -2 in six different species of nonhuman primates and found both viruses to replicate most efficiently in African green monkeys and chimpanzees. We then compared the replication of HPIV-3 in African green monkeys to that in rhesus macaques, which we have used previously, and found that HPIV-3 replicated to higher titer in African green monkeys. In summary, African green monkeys provide a very useful nonhuman primate for the evaluation of HPIV-1, -2, and -3 vaccine candidates, especially for the evaluation of various combinations of these PIV vaccines and for vaccine strategies that employ sequential immunization. Copyright (C) 2000.
AB - Human parainfluenza virus (HPIV) types-1, -2, and -3 are significant causes of both upper and lower respiratory tract disease in infants and children. Although there are two live attenuated vaccines for the prevention of HPIV-3 disease in phase 1 clinical trials, vaccines are not currently available for prevention of HPIV-1 or -2 disease. Our laboratory is developing candidate vaccines for the prevention of HPIV-1, -2, and -3 disease, and a suitable nonhuman primate model is needed for evaluation of these vaccine candidates prior to administration to humans. We evaluated the replication of HPIV-1 and -2 in six different species of nonhuman primates and found both viruses to replicate most efficiently in African green monkeys and chimpanzees. We then compared the replication of HPIV-3 in African green monkeys to that in rhesus macaques, which we have used previously, and found that HPIV-3 replicated to higher titer in African green monkeys. In summary, African green monkeys provide a very useful nonhuman primate for the evaluation of HPIV-1, -2, and -3 vaccine candidates, especially for the evaluation of various combinations of these PIV vaccines and for vaccine strategies that employ sequential immunization. Copyright (C) 2000.
UR - http://www.scopus.com/inward/record.url?scp=0034015968&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0034015968&partnerID=8YFLogxK
U2 - 10.1016/S0264-410X(99)00575-7
DO - 10.1016/S0264-410X(99)00575-7
M3 - Article
C2 - 10738104
AN - SCOPUS:0034015968
SN - 0264-410X
VL - 18
SP - 2462
EP - 2469
JO - Vaccine
JF - Vaccine
IS - 22
ER -